Chronic Pruritus Therapeutics Global Market Report 2025

The chronic pruritus therapeutics market size has grown strongly in recent years. It will grow from $10.17 billion in 2024 to $10.94 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to factors such as the rising prevalence of chronic pruritus, increasing demand for effective treatments, growing regulatory approvals, a rise in product approvals, and an increase in mergers, collaborations, and acquisitions among industry participants.

The chronic pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be attributed to factors such as rising awareness, the increasing prevalence of atopic dermatitis, a growing focus on personalized medicine, the rising incidence of dermatological conditions, and a growing patient population. Key trends during this period include the introduction of innovative medicines, the development of novel biologics and targeted therapies, technological advancements, the integration of advanced drug delivery systems, collaborations between pharmaceutical companies and research institutions, and the adoption of digital health technologies, including telemedicine.

The rising prevalence of atopic dermatitis is expected to drive the growth of the chronic pruritus therapeutics market. Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by symptoms such as redness, itching, dryness, and irritation. It commonly affects individuals with a family history of allergies, asthma, or hay fever. The increasing prevalence of atopic dermatitis can be attributed to factors such as genetic predisposition, environmental changes, lifestyle habits, the hygiene hypothesis, increased allergen exposure, and imbalances in the skin microbiome. Chronic pruritus therapeutics help alleviate the persistent itching associated with atopic dermatitis by targeting the underlying inflammatory pathways, reducing skin irritation, and enhancing patient comfort. For example, in 2022, the International Eczema Council reported that approximately 223 million people worldwide were living with atopic dermatitis, including 43 million children aged 1-4, emphasizing the condition’s high prevalence in early childhood. As a result, the growing prevalence of atopic dermatitis is driving the expansion of the chronic pruritus therapeutics market.

Key companies in the chronic pruritus therapeutics market are focusing on developing innovative treatments, such as intravenous (IV) injection therapies, to improve treatment efficacy and provide quicker relief for patients. IV injections deliver medications such as antihistamines or corticosteroids directly into the bloodstream, offering fast relief from itching and inflammation. For example, in September 2023, Cara Therapeutics Inc., a U.S.-based company, announced that its partner company Maruishi Pharmaceutical Co. Ltd. received approval from Japan’s Ministry of Health, Labour and Welfare for the Korsuva IV injection syringe. This treatment, aimed at pruritus in hemodialysis patients, showed significant improvements in itching scores compared to a placebo in Phase 3 clinical trials and was well-tolerated by patients. The approval also triggered a $1.5 million milestone payment to Cara Therapeutics under the terms of their licensing agreement with Maruishi.

In May 2024, Incyte Corporation, a U.S.-based biopharmaceutical company, acquired Escient Pharmaceuticals for $750 million. This acquisition aims to strengthen Incyte’s Inflammation and Autoimmunity (IAI) pipeline by integrating innovative therapies targeting severe inflammatory diseases. Escient Pharmaceuticals is a U.S.-based biotechnology company specializing in therapeutics for uremic pruritus.

Major players in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic pruritus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pruritus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic pruritus therapy refers to treatments designed to manage or relieve persistent itching (pruritus) that lasts for six weeks or more. Managing chronic pruritus involves a combination of therapies tailored to the underlying cause, with treatment adjustments based on the patient's response.

The main product types for chronic pruritus therapeutics include corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressants, calcineurin inhibitors, and other treatments. Corticosteroids are medications that reduce inflammation and itching by suppressing the immune system’s response, making them effective for treating chronic pruritus and inflammatory skin conditions. These products are used for various conditions, including atopic dermatitis, allergic contact dermatitis, urticaria, and others. They are distributed through multiple channels, such as hospital pharmacies, drug stores, retail pharmacies, and online providers.

The chronic pruritus therapeutics market research report is one of a series of new reports that provides chronic pruritus therapeutics market statistics, including the chronic pruritus therapeutics industry global market size, regional shares, competitors with the chronic pruritus therapeutics market share, detailed chronic pruritus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pruritus therapeutics industry. This chronic pruritus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic pruritus therapeutics market consists of sales of capsaicin creams, jak inhibitors, systemic therapies, phototherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.